Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance

Rudra Prasad Dutta, Heng-Huan Lee, Ravi Prakash Shukla, Violetta V Leshchenko, Fanye Meng, Fangfang Yan, Yang Liu, Husnu Kaniskan, Jian Jin, Lapo Alinari, Michael Wang, Samir Parekh

Blood (2024) 144 (Supplement 1): 1402.

https://doi.org/10.1182/blood-2024-210591

Published: 2024

Journal Articles

SOX11 augments BCR signaling to drive MCL-like tumor development

Pei-Yu Kuo, Shashidhar S. Jatiani, Adeeb H. Rahman, Donna Edwards, Zewei Jiang, Katya Ahr, Deepak Perumal, Violetta V. Leshchenko, Joshua Brody, Rita Shaknovich, B. Hilda Ye, Samir Parekh

Blood (2018) 131 (20): 2247–2255.

https://doi.org/10.1182/blood-2018-02-832535

Published: 2018

Includes: Supplemental data

Journal Articles

MAGE-a Mediate Resistance to Chemotherapy in Multiple Myeloma through Regulation of Bcl-2 Proteins

Hearn Jay Cho, MD PhD, Anna Mei, MS, Jami Fukui, MD, Kaity Tung, BS, Violetta V Leshchenko, PhD, Alessandro Lagana, PhD, Manishkumar Patel, Seunghee Kim-Schulze, PhD, Deepak Perumal, PhD, Ajai Chari, MD, Sundar Jagannath, MD, Samir Parekh, MD

Blood (2016) 128 (22): 3277.

https://doi.org/10.1182/blood.V128.22.3277.3277

Published: 2016

Journal Articles

Integrative Network Analysis of Newly Diagnosed Multiple Myeloma Identifies a Novel RNA-Seq Based High Riskgene Signature

Alessandro Lagana, PhD, Deepak Perumal, PhD, David Melnekoff, BS, Ben Readhead, MBBS, Brian Kidd, PhD, Violetta V Leshchenko, PhD, Pei-Yu Kuo, MS, Jonathan J Keats, PhD, Mary Derome, MS, Jennifer Yesil, MS, Daniel Auclair, PhD, Deepu Madduri, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2016) 128 (22): 3285.

https://doi.org/10.1182/blood.V128.22.3285.3285

Published: 2016

Journal Articles

Aberrant a-to-I RNA Editing and Prognostic Impact of Adar in Multiple Myeloma Patients with 1q Amplification

Alessandro Lagana, PhD, Deepak Perumal, PhD, Violetta V Leshchenko, PhD, Pei-Yu Kuo, MS, Brian Kidd, PhD, Jonathan J Keats, PhD, Mary Derome, MS, Jennifer Yesil, MS, Daniel Auclair, PhD, Deepu Madduri, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2016) 128 (22): 357.

https://doi.org/10.1182/blood.V128.22.357.357

Published: 2016

Journal Articles

Network Modeling Reveals CDC42BPA and CLEC11A As Novel Driver Genes of t(4; 14) Multiple Myeloma

Deepak Perumal, PhD, Alessandro Lagana', PhD, David Melnekoff, BS, Ben Readhead, MBBS, Brian Kidd, PhD, Violetta V Leshchenko, PhD, Pei-Yu Kuo, MS, Jennifer Yesil, MS, Mary Derome, MS, Daniel Auclair, PhD, Deepu Madduri, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2016) 128 (22): 802.

https://doi.org/10.1182/blood.V128.22.802.802

Published: 2016

Journal Articles

SOX11 Cooperates with CCND1 in Mantle Cell Lymphoma Pathogenesis

Pei-Yu Kuo, MS, Zewei Jiang, MD, Deepak Perumal, PhD, Violetta V Leshchenko, PhD, Alessandro Lagana', PhD, Samuel G. Katz, MD PhD, Loren D. Walensky, MD PhD, Rita Shaknovich, MD, PhD, B. Hilda Ye, PhD, Samir Parekh, MD

Blood (2015) 126 (23): 1253.

https://doi.org/10.1182/blood.V126.23.1253.1253

Published: 2015

Journal Articles

A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma

Blood (2015) 126 (23): 4226.

https://doi.org/10.1182/blood.V126.23.4226.4226

Published: 2015

Journal Articles

Patient-Specific Mutation-Derived Tumor Antigens As Targets for Cancer Immunotherapy in Multiple Myeloma

Deepak Perumal, PhD, Alessandro Lagana', PhD, Alex Rubinsteyn, PhD, John P Finnigan, Jr., BS, Pei-Yu Kuo, MS, Violetta V Leshchenko, PhD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Jeff Hammerbacher, BA, Eric Schadt, PhD, Nina Bhardwaj, MD PhD, Samir Parekh, MD

Blood (2015) 126 (23): 1851.

https://doi.org/10.1182/blood.V126.23.1851.1851

Published: 2015

Journal Articles

Weighted Gene Co-Expression Network Analysis (WGCNA) Identifies Highly Proliferative Myeloma Subgroup Responsive to CDK4/ARK5 Inhibition

Deepak Perumal, PhD, Violetta V. Leshchenko, PhD, Pei-Yu Kuo, MS, Zewei Jiang, MD, Ben Readhead, MBBS, Caroline Eden, BS, Sai Krishna Athaluri Divakar, PhD, Weijia Zhang, PhD, Hearn Jay Cho, MD PhD, Ajai Chari, MD, M.V.Ramana Reddy, PhD, E. Premkumar Reddy, PhD, Joel Dudley, PhD, Sundar Jagannath, MD, Samir Parekh, MD

Blood (2014) 124 (21): 3445.

https://doi.org/10.1182/blood.V124.21.3445.3445

Published: 2014

Journal Articles

Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkin’s Lymphoma and Previously Untreated Mantle Cell Lymphoma

Stephen Spurgeon, MD, Kamal Sharma, DO, David F. Claxton, MD, Christopher Ehmann, MD, Sara Shimko, BS, August Stewart, Samir Parekh, MD, Violetta V. Leshchenko, PhD, Yiyi Chen, PhD, Motomi Mori, Jeffrey J. Pu, MD PhD, Elliot Epner, MD PhD

Blood (2014) 124 (21): 1714.

https://doi.org/10.1182/blood.V124.21.1714.1714

Published: 2014

Journal Articles

High-Resolution Genomic Methylation Analysis Using Next Generation Sequencing Identifies Loci Associated With Differential Prognosis In Mantle Cell Lymphoma Patients Treated With Bortezomib + DA-EPOCH-R

Violetta V. Leshchenko, PhD, Pei-Yu Kuo, MS, Deepak Perumal, PhD, Melissa J Fazzari, PhD, Francine E. Garrett-Bakelman, MD, PhD, Nakhle S Saba, MD, Delong Liu, PhD, Weijia Zhang, PhD, Joshua Brody, MD, Ari M. Melnick, MD, Kieron Dunleavy, MD, Wyndham H Wilson, MD, PhD, Adrian Wiestner, MD, PhD, Samir Parekh, MD

Blood (2013) 122 (21): 3760.

https://doi.org/10.1182/blood.V122.21.3760.3760

Published: 2013

Journal Articles

Combined Epigenetic and Immunotherapy For Newly Diagnosed Mantle Cell Lymphoma: Correlative Studies Suggest The Importance Of Enhanced ADCC, Mechanisms of Resistance and Cyclin D1 Nuclear Localization Genotype

Kamal Sharma, DO, Violetta V. Leshchenko, PhD, Zainul Hasanali, BS, August Stuart, MS, Sara Shimko, BS, Stephen E Spurgeon, MD, Samir Parekh, MD, Elliot M Epner, MD Phd

Blood (2013) 122 (21): 3063.

https://doi.org/10.1182/blood.V122.21.3063.3063

Published: 2013

Journal Articles

SOX11 Directly Represses Wnt/β-Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment

Pei-Yu Kuo, MS, Violetta V. Leshchenko, PhD, Melissa J Fazzari, PhD, Tobias A. Gellen, Javeed Iqbal, M.Sc, PhD, Stefanie Baumgartner-Wennerholm, MD, Lina Nygren, MD, K. Stephen Suh, PhD, Andre Goy, MD, David T. Yang, MD, Wing-Chung Chan, MD, Brad S Kahl, MD, Amit Verma, MD, Randy D. Gascoyne, MD, Eva Kimby, M.D., Ph.D., Birgitta Sander, MD, Ph.D., B. Hilda Ye, PhD, Ari Melnick, MD, Samir Parekh, MD

Blood (2012) 120 (21): 895.

https://doi.org/10.1182/blood.V120.21.895.895

Published: 2012

Journal Articles

Vorinostat (SAHA), Cladribine, and Rituximab in Previously Untreated Mantle Cell Lymphoma: Updated Results From a Phase I/II Trial

Stephen E Spurgeon, MD, Kamal Sharma, DO, David F. Claxton, MD, Christopher W. Ehmann, MD, Carla Gallagher, PhD, Sara Shimko, BS, August Stewart, Samir Parekh, MD, Violetta V. Leshchenko, PhD, Yiyi Chen, PhD, Elliot M Epner, MD, PhD

Blood (2012) 120 (21): 3675.

https://doi.org/10.1182/blood.V120.21.3675.3675

Published: 2012

Journal Articles

High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma

Pei-Yu Kuo, MS, Violetta V. Leshchenko, PhD, Tobias A. Gellen, Netha Ulahannan, MS, Paul Zumbo, BA, BS, Christopher E. Mason, PhD, Wyndham H. Wilson, MD, PhD, Adrian Wiestner, MD, PhD, K. Stephen Suh, PhD, Andre Goy, MD, David T. Yang, MD, Brad S. Kahl, MD, Randy D. Gascoyne, MD, Ari Melnick, MD, Samir Parekh, MD

Blood (2011) 118 (21): 585.

https://doi.org/10.1182/blood.V118.21.585.585

Published: 2011

Journal Articles

A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma

Stephen Spurgeon, MD, Andy I Chen, MD, PhD, Craig Okada, MD, PhD, Samir Parekh, MD, Violetta V. Leshchenko, PhD, Gundula Palmbach, Bashi Ratterree, RN, Nan Subbiah, Christine Capper, RN, Elliot M Epner, MD, PhD

Blood (2011) 118 (21): 441.

https://doi.org/10.1182/blood.V118.21.441.441

Published: 2011

Journal Articles

High-Resolution Sequencing Identifies NOXA1 De-Methylation As a Novel Strategy to Overcome Bortezomib Resistance in Mantle Cell Lymphoma

Violetta V. Leshchenko, PhD, Pei-Yu Kuo, MS, Netha Ulahannan, MS, Elana Braunschweig, Yiting Yu, PhD, K. Stephen Suh, PhD, Marc A. Weniger, PhD, Andre Goy, MD, Wyndham H. Wilson, MD, PhD, Adrian Wiestner, MD, PhD, Amit Verma, MD, Samir Parekh, MD

Blood (2011) 118 (21): 557.

https://doi.org/10.1182/blood.V118.21.557.557

Published: 2011

Journal Articles

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

Matko Kalac, Luigi Scotto, Enrica Marchi, Jennifer Amengual, Venkatraman E. Seshan, Govind Bhagat, Netha Ulahannan, Violetta V. Leshchenko, Alexis M. Temkin, Samir Parekh, Benjamin Tycko, Owen A. O'Connor

Blood (2011) 118 (20): 5506–5516.

https://doi.org/10.1182/blood-2011-02-336891

Published: 2011

Includes: Supplemental data

Journal Articles

Genomic and Pathway Connectivity Analyses Identify Novel Strategies to Overcome mTOR Inhibitor Resistance In DLBCL

Adam M. Petrich, MD, Violetta V. Leshchenko, PhD, Pei-Yu Kuo, MS, B. Hilda Ye, PhD, Joseph A Sparano, MD, Samir Parekh, MD

Blood (2010) 116 (21): 436.

https://doi.org/10.1182/blood.V116.21.436.436

Published: 2010

NARROW

Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance

SOX11 augments BCR signaling to drive MCL-like tumor development

MAGE-a Mediate Resistance to Chemotherapy in Multiple Myeloma through Regulation of Bcl-2 Proteins

Integrative Network Analysis of Newly Diagnosed Multiple Myeloma Identifies a Novel RNA-Seq Based High Riskgene Signature

Aberrant a-to-I RNA Editing and Prognostic Impact of Adar in Multiple Myeloma Patients with 1q Amplification

Network Modeling Reveals CDC42BPA and CLEC11A As Novel Driver Genes of t(4; 14) Multiple Myeloma

SOX11 Cooperates with CCND1 in Mantle Cell Lymphoma Pathogenesis

A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma

Patient-Specific Mutation-Derived Tumor Antigens As Targets for Cancer Immunotherapy in Multiple Myeloma

Weighted Gene Co-Expression Network Analysis (WGCNA) Identifies Highly Proliferative Myeloma Subgroup Responsive to CDK4/ARK5 Inhibition

Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkin’s Lymphoma and Previously Untreated Mantle Cell Lymphoma

High-Resolution Genomic Methylation Analysis Using Next Generation Sequencing Identifies Loci Associated With Differential Prognosis In Mantle Cell Lymphoma Patients Treated With Bortezomib + DA-EPOCH-R

Combined Epigenetic and Immunotherapy For Newly Diagnosed Mantle Cell Lymphoma: Correlative Studies Suggest The Importance Of Enhanced ADCC, Mechanisms of Resistance and Cyclin D1 Nuclear Localization Genotype

SOX11 Directly Represses Wnt/β-Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment

Vorinostat (SAHA), Cladribine, and Rituximab in Previously Untreated Mantle Cell Lymphoma: Updated Results From a Phase I/II Trial

High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma

A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma

High-Resolution Sequencing Identifies NOXA1 De-Methylation As a Novel Strategy to Overcome Bortezomib Resistance in Mantle Cell Lymphoma

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

Genomic and Pathway Connectivity Analyses Identify Novel Strategies to Overcome mTOR Inhibitor Resistance In DLBCL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only